PI4KIIIβ-IN-10 | CAS#1881233-39-1 | PI4KIIIβ inhibitor

MedKoo Cat#: 534624 | Name: PI4KIIIβ-IN-10

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PI4KIIIβ-IN-10 (PI4KIIIbeta-IN-10) is a novel potent PI4KIIIβ inhibitor (IC50 3.6 nM).

Chemical Structure

PI4KIIIβ-IN-10

CAS#1881233-39-1

Theoretical Analysis

MedKoo Cat#: 534624

Name: PI4KIIIβ-IN-10

CAS#: 1881233-39-1

Chemical Formula: C22H25N3O5S2

Exact Mass: 475.1236

Molecular Weight: 475.58

Elemental Analysis: C, 55.56; H, 5.30; N, 8.84; O, 16.82; S, 13.48

Price and Availability

Size	Price	Availability
100mg	USD 1,250.00	2 Weeks
200mg	USD 1,950.00	2 Weeks
500mg	USD 2,850.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 6,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PI4KIIIβ-IN-10; PI4KIIIbeta-IN-10; PI4KIIIbeta-IN 10; PI4KIIIbeta-IN10;

IUPAC/Chemical Name

N-[5-[3-[(4-hydroxyphenyl)sulfamoyl]-4-methoxyphenyl]-4-methyl-1,3-thiazol-2-yl]-2,2-dimethylpropanamide

InChi Key

PLUYFBRIGUAKBR-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H25N3O5S2/c1-13-19(31-21(23-13)24-20(27)22(2,3)4)14-6-11-17(30-5)18(12-14)32(28,29)25-15-7-9-16(26)10-8-15/h6-12,25-26H,1-5H3,(H,23,24,27)

SMILES Code

CC(C)(C)C(NC1=NC(C)=C(C2=CC=C(OC)C(S(=O)(NC3=CC=C(O)C=C3)=O)=C2)S1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC50 of 3.6 nM.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	125.0	262.84

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 475.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Chakrasali P, Hwang D, Lee JY, Jung E, Lee HL, Reneesh A, Skarka A, Musilek K, Nguyen NH, Shin JS, Jung YS. 7-Amino-3-phenyl-2-methyl-pyrazolopyrimidine derivatives inhibit human rhinovirus replication. Eur J Med Chem. 2024 Oct 5;276:116690. doi: 10.1016/j.ejmech.2024.116690. Epub 2024 Jul 17. PMID: 39032404. 2: Simsek Papur O, Glatz JFC, Luiken JJFP. Protein kinase-D1 and downstream signaling mechanisms involved in GLUT4 translocation in cardiac muscle. Biochim Biophys Acta Mol Cell Res. 2024 Aug;1871(6):119748. doi: 10.1016/j.bbamcr.2024.119748. Epub 2024 May 8. PMID: 38723678. 3: G Vishakantegowda A, Hwang D, Chakrasali P, Jung E, Lee JY, Shin JS, Jung YS. Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents. RSC Med Chem. 2023 Dec 21;15(2):704-719. doi: 10.1039/d3md00630a. Erratum in: RSC Med Chem. 2024 Jun 12;15(6):2196-2197. doi: 10.1039/d4md90022g. PMID: 38389877; PMCID: PMC10880896. 4: Sang Y, Niu C, Xu J, Zhu T, You S, Wang J, Zhang L, Du X, Zhang H. PI4KIIIβ- Mediated Phosphoinositides Metabolism Regulates Function of the VTA Dopaminergic Neurons and Depression-Like Behavior. J Neurosci. 2024 Mar 13;44(11):e0555232024. doi: 10.1523/JNEUROSCI.0555-23.2024. PMID: 38267258; PMCID: PMC10941068. 5: Stalder D, Yakunin I, Pereira C, Eden J, Gershlick DC. Recruitment of PI4KIIIβ to the Golgi by ACBD3 is dependent on an upstream pathway of a SNARE complex and golgins. Mol Biol Cell. 2024 Feb 1;35(2):ar20. doi: 10.1091/mbc.E23-09-0376. Epub 2023 Dec 22. PMID: 38134218; PMCID: PMC7615549. 6: Cosgrove B, Grant EK, Bertrand S, Down KD, Somers DO, P Evans J, Tomkinson NCO, Barker MD. Covalent targeting of non-cysteine residues in PI4KIIIβ. RSC Chem Biol. 2023 Oct 17;4(12):1111-1122. doi: 10.1039/d3cb00142c. PMID: 38033723; PMCID: PMC10685791. 7: Obata Y, Kurokawa K, Tojima T, Natsume M, Shiina I, Takahashi T, Abe R, Nakano A, Nishida T. Golgi retention and oncogenic KIT signaling via PLCγ2-PKD2-PI4KIIIβ activation in gastrointestinal stromal tumor cells. Cell Rep. 2023 Sep 26;42(9):113035. doi: 10.1016/j.celrep.2023.113035. Epub 2023 Aug 23. PMID: 37616163. 8: Bura A, Čabrijan S, Đurić I, Bruketa T, Jurak Begonja A. A Plethora of Functions Condensed into Tiny Phospholipids: The Story of PI4P and PI(4,5)P2. Cells. 2023 May 17;12(10):1411. doi: 10.3390/cells12101411. PMID: 37408244; PMCID: PMC10216963. 9: Boutry M, DiGiovanni LF, Demers N, Fountain A, Mamand S, Botelho RJ, Kim PK. Arf1-PI4KIIIβ positive vesicles regulate PI(3)P signaling to facilitate lysosomal tubule fission. J Cell Biol. 2023 Sep 4;222(9):e202205128. doi: 10.1083/jcb.202205128. Epub 2023 Jun 8. PMID: 37289133; PMCID: PMC10250553. 10: Tan X, Xiao GY, Wang S, Shi L, Zhao Y, Liu X, Yu J, Russell WK, Creighton CJ, Kurie JM. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. J Clin Invest. 2023 Apr 3;133(7):e165863. doi: 10.1172/JCI165863. PMID: 36757799; PMCID: PMC10065074. 11: Crivelli SM, Giovagnoni C, Zhu Z, Tripathi P, Elsherbini A, Quadri Z, Pu J, Zhang L, Ferko B, Berkes D, Spassieva SD, Martinez-Martinez P, Bieberich E. Function of ceramide transfer protein for biogenesis and sphingolipid composition of extracellular vesicles. J Extracell Vesicles. 2022 Jun;11(6):e12233. doi: 10.1002/jev2.12233. PMID: 35642450; PMCID: PMC9156972. 12: Ibezim A, Madukaife MS, Osigwe SC, Engel N, Karuppasamy R, Ntie-Kang F. Fragment-based virtual screening discovers potential new Plasmodium PI4KIIIβ ligands. BMC Chem. 2022 Mar 24;16(1):19. doi: 10.1186/s13065-022-00812-2. PMID: 35331319; PMCID: PMC8944149. 13: Dang N, Waer M, Sprangers B, Lin Y. Establishment of operational tolerance to sustain antitumor immunotherapy. J Heart Lung Transplant. 2022 May;41(5):568-577. doi: 10.1016/j.healun.2022.01.019. Epub 2022 Jan 31. PMID: 35184967. 14: Grazia Martina M, Vicenti I, Bauer L, Crespan E, Rango E, Boccuto A, Olivieri N, Incerti M, Zwaagstra M, Allodi M, Bertoni S, Dreassi E, Zazzi M, van Kuppeveld FJM, Maga G, Radi M. Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses. ChemMedChem. 2021 Dec 6;16(23):3548-3552. doi: 10.1002/cmdc.202100483. Epub 2021 Sep 7. PMID: 34382337; PMCID: PMC8427023. 15: Lu JY, Brewer G, Li ML, Lin KZ, Huang CC, Yen LC, Lin JY. Secretory Carrier Membrane Protein 3 Interacts with 3A Viral Protein of Enterovirus and Participates in Viral Replication. Microbiol Spectr. 2021 Sep 3;9(1):e0047521. doi: 10.1128/Spectrum.00475-21. Epub 2021 Aug 11. PMID: 34378951; PMCID: PMC8552740. 16: Shi L, Tan X, Liu X, Yu J, Bota-Rabassedas N, Niu Y, Luo J, Xi Y, Zong C, Creighton CJ, Glenn JS, Wang J, Kurie JM. Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):e2023537118. doi: 10.1073/pnas.2023537118. PMID: 34155143; PMCID: PMC8237628. 17: Kutchukian C, Vivas O, Casas M, Jones JG, Tiscione SA, Simó S, Ory DS, Dixon RE, Dickson EJ. NPC1 regulates the distribution of phosphatidylinositol 4-kinases at Golgi and lysosomal membranes. EMBO J. 2021 Jul 1;40(13):e105990. doi: 10.15252/embj.2020105990. Epub 2021 May 21. PMID: 34019311; PMCID: PMC8246069. 18: Tan YW, Yam WK, Kooi RJW, Westman J, Arbrandt G, Chu JJH. Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition. Sci Rep. 2021 May 6;11(1):9719. doi: 10.1038/s41598-021-89271-8. PMID: 33958691; PMCID: PMC8102518. 19: Highland CM, Fromme JC. Arf1 directly recruits the Pik1-Frq1 PI4K complex to regulate the final stages of Golgi maturation. Mol Biol Cell. 2021 May 1;32(10):1064-1080. doi: 10.1091/mbc.E21-02-0069. Epub 2021 Mar 31. PMID: 33788598; PMCID: PMC8101487. 20: Arendse LB, Wyllie S, Chibale K, Gilbert IH. Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. ACS Infect Dis. 2021 Mar 12;7(3):518-534. doi: 10.1021/acsinfecdis.0c00724. Epub 2021 Feb 16. PMID: 33590753; PMCID: PMC7961706.